Does the media favor NVCT or DTIL?

In the previous week, Precision BioSciences had 1 more articles in the media than Nuvectis Pharma. MarketBeat recorded 5 mentions for Precision BioSciences and 4 mentions for Nuvectis Pharma. Nuvectis Pharma's average media sentiment score of 0.98 beat Precision BioSciences' score of 0.47 indicating that Nuvectis Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvectis Pharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Precision BioSciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor AURA or DTIL?

In the previous week, Precision BioSciences had 3 more articles in the media than Aura Biosciences. MarketBeat recorded 5 mentions for Precision BioSciences and 2 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 1.28 beat Precision BioSciences' score of 0.47 indicating that Aura Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aura Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Precision BioSciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to DTIL or PRME?

In the previous week, Prime Medicine had 1 more articles in the media than Precision BioSciences. MarketBeat recorded 6 mentions for Prime Medicine and 5 mentions for Precision BioSciences. Prime Medicine's average media sentiment score of 0.58 beat Precision BioSciences' score of 0.47 indicating that Prime Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precision BioSciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prime Medicine 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor DBVT or DTIL?

In the previous week, Precision BioSciences had 2 more articles in the media than DBV Technologies. MarketBeat recorded 5 mentions for Precision BioSciences and 3 mentions for DBV Technologies. Precision BioSciences' average media sentiment score of 0.47 beat DBV Technologies' score of 0.04 indicating that Precision BioSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DBV Technologies 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Precision BioSciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Precision BioSciences (DTIL) Competitors

$6.18 +0.08 (+1.33%)

As of 09:57 AM Eastern

Compare

DTIL vs. MDXG, NVCT, AURA, PRME, and DBVT

Should you buy Precision BioSciences stock or one of its competitors? Precision BioSciences's main competitors and comparable companies include MiMedx Group (MDXG), Nuvectis Pharma (NVCT), Aura Biosciences (AURA), Prime Medicine (PRME), and DBV Technologies (DBVT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Precision BioSciences compare to MiMedx Group?

Precision BioSciences (NASDAQ:DTIL) and MiMedx Group (NASDAQ:MDXG) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

MiMedx Group has a net margin of 1.76% compared to Precision BioSciences' net margin of -96.73%. MiMedx Group's return on equity of 12.09% beat Precision BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precision BioSciences	-96.73%	-72.52%	-32.25%
MiMedx Group	1.76%	12.09%	9.22%

In the previous week, Precision BioSciences had 4 more articles in the media than MiMedx Group. MarketBeat recorded 5 mentions for Precision BioSciences and 1 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 0.94 beat Precision BioSciences' score of 0.47 indicating that MiMedx Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Precision BioSciences	Neutral
MiMedx Group	Positive

Precision BioSciences has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market. Comparatively, MiMedx Group has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market.

Precision BioSciences currently has a consensus target price of $32.25, indicating a potential upside of 428.69%. MiMedx Group has a consensus target price of $8.57, indicating a potential upside of 82.76%. Given Precision BioSciences' higher possible upside, equities research analysts clearly believe Precision BioSciences is more favorable than MiMedx Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

38.0% of Precision BioSciences shares are owned by institutional investors. Comparatively, 79.2% of MiMedx Group shares are owned by institutional investors. 2.7% of Precision BioSciences shares are owned by company insiders. Comparatively, 2.5% of MiMedx Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

MiMedx Group has higher revenue and earnings than Precision BioSciences. Precision BioSciences is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precision BioSciences	$34.26M	4.91	-$45.72M	-$2.80	N/A
MiMedx Group	$418.63M	1.63	$48.58M	$0.04	117.25

Summary

MiMedx Group beats Precision BioSciences on 11 of the 16 factors compared between the two stocks.

How does Precision BioSciences compare to Nuvectis Pharma?

Nuvectis Pharma (NASDAQ:NVCT) and Precision BioSciences (NASDAQ:DTIL) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk and earnings.

Nuvectis Pharma has a net margin of 0.00% compared to Precision BioSciences' net margin of -96.73%. Precision BioSciences' return on equity of -72.52% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvectis Pharma	N/A	-184.25%	-105.24%
Precision BioSciences	-96.73%	-72.52%	-32.25%

96.8% of Nuvectis Pharma shares are held by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are held by institutional investors. 28.6% of Nuvectis Pharma shares are held by company insiders. Comparatively, 2.7% of Precision BioSciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Precision BioSciences had 1 more articles in the media than Nuvectis Pharma. MarketBeat recorded 5 mentions for Precision BioSciences and 4 mentions for Nuvectis Pharma. Nuvectis Pharma's average media sentiment score of 0.98 beat Precision BioSciences' score of 0.47 indicating that Nuvectis Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvectis Pharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Precision BioSciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nuvectis Pharma has higher earnings, but lower revenue than Precision BioSciences. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A
Precision BioSciences	$34.26M	4.91	-$45.72M	-$2.80	N/A

Nuvectis Pharma currently has a consensus target price of $36.25, suggesting a potential upside of 99.72%. Precision BioSciences has a consensus target price of $32.25, suggesting a potential upside of 428.69%. Given Precision BioSciences' higher possible upside, analysts clearly believe Precision BioSciences is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Nuvectis Pharma has a beta of -0.24, suggesting that its stock price is 124% less volatile than the broader market. Comparatively, Precision BioSciences has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market.

Summary

Nuvectis Pharma beats Precision BioSciences on 8 of the 15 factors compared between the two stocks.

How does Precision BioSciences compare to Aura Biosciences?

Aura Biosciences (NASDAQ:AURA) and Precision BioSciences (NASDAQ:DTIL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

Aura Biosciences presently has a consensus price target of $17.50, suggesting a potential upside of 179.11%. Precision BioSciences has a consensus price target of $32.25, suggesting a potential upside of 428.69%. Given Precision BioSciences' stronger consensus rating and higher possible upside, analysts plainly believe Precision BioSciences is more favorable than Aura Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Aura Biosciences has a net margin of 0.00% compared to Precision BioSciences' net margin of -96.73%. Precision BioSciences' return on equity of -72.52% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-73.18%	-62.00%
Precision BioSciences	-96.73%	-72.52%	-32.25%

In the previous week, Precision BioSciences had 3 more articles in the media than Aura Biosciences. MarketBeat recorded 5 mentions for Precision BioSciences and 2 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 1.28 beat Precision BioSciences' score of 0.47 indicating that Aura Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aura Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Precision BioSciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

96.8% of Aura Biosciences shares are held by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are held by institutional investors. 1.9% of Aura Biosciences shares are held by insiders. Comparatively, 2.7% of Precision BioSciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Precision BioSciences has higher revenue and earnings than Aura Biosciences. Aura Biosciences is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.75	N/A
Precision BioSciences	$34.26M	4.91	-$45.72M	-$2.80	N/A

Aura Biosciences has a beta of 0.41, suggesting that its share price is 59% less volatile than the broader market. Comparatively, Precision BioSciences has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market.

Summary

Precision BioSciences beats Aura Biosciences on 10 of the 14 factors compared between the two stocks.

How does Precision BioSciences compare to Prime Medicine?

Precision BioSciences (NASDAQ:DTIL) and Prime Medicine (NASDAQ:PRME) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk, media sentiment and profitability.

Precision BioSciences has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market. Comparatively, Prime Medicine has a beta of 2.37, suggesting that its share price is 137% more volatile than the broader market.

38.0% of Precision BioSciences shares are owned by institutional investors. Comparatively, 70.4% of Prime Medicine shares are owned by institutional investors. 2.7% of Precision BioSciences shares are owned by insiders. Comparatively, 16.0% of Prime Medicine shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Precision BioSciences has higher revenue and earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precision BioSciences	$34.26M	4.91	-$45.72M	-$2.80	N/A
Prime Medicine	$4.63M	130.06	-$201.14M	-$1.06	N/A

Precision BioSciences presently has a consensus target price of $32.25, suggesting a potential upside of 428.69%. Prime Medicine has a consensus target price of $7.47, suggesting a potential upside of 125.07%. Given Precision BioSciences' higher probable upside, analysts clearly believe Precision BioSciences is more favorable than Prime Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Precision BioSciences has a net margin of -96.73% compared to Prime Medicine's net margin of -4,613.11%. Precision BioSciences' return on equity of -72.52% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precision BioSciences	-96.73%	-72.52%	-32.25%
Prime Medicine	-4,613.11%	-188.27%	-59.11%

In the previous week, Prime Medicine had 1 more articles in the media than Precision BioSciences. MarketBeat recorded 6 mentions for Prime Medicine and 5 mentions for Precision BioSciences. Prime Medicine's average media sentiment score of 0.58 beat Precision BioSciences' score of 0.47 indicating that Prime Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precision BioSciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prime Medicine	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Prime Medicine beats Precision BioSciences on 10 of the 16 factors compared between the two stocks.

How does Precision BioSciences compare to DBV Technologies?

DBV Technologies (NASDAQ:DBVT) and Precision BioSciences (NASDAQ:DTIL) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment.

Precision BioSciences has a net margin of -96.73% compared to DBV Technologies' net margin of -3,506.53%. Precision BioSciences' return on equity of -72.52% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-3,506.53%	-119.33%	-84.43%
Precision BioSciences	-96.73%	-72.52%	-32.25%

In the previous week, Precision BioSciences had 2 more articles in the media than DBV Technologies. MarketBeat recorded 5 mentions for Precision BioSciences and 3 mentions for DBV Technologies. Precision BioSciences' average media sentiment score of 0.47 beat DBV Technologies' score of 0.04 indicating that Precision BioSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DBV Technologies	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Precision BioSciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Precision BioSciences has higher revenue and earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$5.64M	100.67	-$146.95M	-$3.51	N/A
Precision BioSciences	$34.26M	4.91	-$45.72M	-$2.80	N/A

71.7% of DBV Technologies shares are held by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are held by institutional investors. 1.1% of DBV Technologies shares are held by company insiders. Comparatively, 2.7% of Precision BioSciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

DBV Technologies presently has a consensus target price of $48.50, indicating a potential upside of 437.10%. Precision BioSciences has a consensus target price of $32.25, indicating a potential upside of 428.69%. Given DBV Technologies' stronger consensus rating and higher possible upside, research analysts clearly believe DBV Technologies is more favorable than Precision BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

DBV Technologies has a beta of -1.04, meaning that its stock price is 204% less volatile than the broader market. Comparatively, Precision BioSciences has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market.

Summary

Precision BioSciences beats DBV Technologies on 10 of the 15 factors compared between the two stocks.

Get Precision BioSciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DTIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DTIL vs. The Competition

Export

Metric	Precision BioSciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$170.98M	$3.93B	$7.26B	$13.21B
Dividend Yield	N/A	3.65%	2.52%	22.89%
P/E Ratio	-2.21	11.31	206.66	19.94
Price / Sales	5.00	1,148.46	562.21	81.34
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	1.54	17.08	10.75	6.03
Net Income	-$45.72M	-$22.69M	$3.50B	$380.34M
7 Day Performance	-0.72%	-4.43%	-2.91%	-2.34%
1 Month Performance	-9.55%	-12.48%	-7.38%	-5.31%
1 Year Performance	6.07%	7.60%	2.96%	-2.94%

Precision BioSciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DTIL Precision BioSciences	3.1614 of 5 stars	$6.21 +1.7%	$32.25 +419.7%	+9.7%	$170.98M	$34.26M	N/A	67
MDXG MiMedx Group	3.2949 of 5 stars	$4.62 +1.5%	$8.57 +85.5%	-28.0%	$673.41M	$355.17M	115.53	808	Gap Down
NVCT Nuvectis Pharma	2.3786 of 5 stars	$20.03 -6.4%	$36.25 +81.0%	+193.2%	$653.78M	N/A	N/A	13
AURA Aura Biosciences	2.1807 of 5 stars	$6.17 -0.8%	$17.50 +183.6%	+2.3%	$639.89M	N/A	N/A	113	Analyst Forecast
PRME Prime Medicine	3.4982 of 5 stars	$3.50 +9.0%	$7.47 +113.5%	-41.2%	$634.83M	$4.63M	N/A	146	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DTIL) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Precision BioSciences (DTIL) Competitors

DTIL vs. MDXG, NVCT, AURA, PRME, and DBVT

How does Precision BioSciences compare to MiMedx Group?

Summary

How does Precision BioSciences compare to Nuvectis Pharma?

Summary

How does Precision BioSciences compare to Aura Biosciences?

Summary

How does Precision BioSciences compare to Prime Medicine?

Summary

How does Precision BioSciences compare to DBV Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DTIL vs. The Competition

Precision BioSciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Precision BioSciences (DTIL) Competitors

DTIL vs. MDXG, NVCT, AURA, PRME, and DBVT

How does Precision BioSciences compare to MiMedx Group?

Is DTIL or MDXG more profitable?

Does the media favor DTIL or MDXG?

Which has more risk & volatility, DTIL or MDXG?

Do analysts prefer DTIL or MDXG?

Do institutionals and insiders believe in DTIL or MDXG?

Which has higher valuation and earnings, DTIL or MDXG?

Summary

How does Precision BioSciences compare to Nuvectis Pharma?

Is NVCT or DTIL more profitable?

Do insiders & institutionals have more ownership in NVCT or DTIL?

Does the media favor NVCT or DTIL?

Which has higher earnings & valuation, NVCT or DTIL?

Do analysts rate NVCT or DTIL?

Which has more risk & volatility, NVCT or DTIL?

Summary

How does Precision BioSciences compare to Aura Biosciences?

Do analysts recommend AURA or DTIL?

Is AURA or DTIL more profitable?

Does the media favor AURA or DTIL?

Do institutionals and insiders have more ownership in AURA or DTIL?

Which has stronger valuation & earnings, AURA or DTIL?

Which has more risk and volatility, AURA or DTIL?

Summary

How does Precision BioSciences compare to Prime Medicine?

Which has more volatility & risk, DTIL or PRME?

Do institutionals & insiders have more ownership in DTIL or PRME?

Which has higher valuation & earnings, DTIL or PRME?

Do analysts prefer DTIL or PRME?

Is DTIL or PRME more profitable?

Does the media refer more to DTIL or PRME?

Summary

How does Precision BioSciences compare to DBV Technologies?

Is DBVT or DTIL more profitable?

Does the media favor DBVT or DTIL?

Which has stronger valuation and earnings, DBVT or DTIL?

Do insiders & institutionals hold more shares of DBVT or DTIL?

Do analysts prefer DBVT or DTIL?

Which has more risk and volatility, DBVT or DTIL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DTIL vs. The Competition

Precision BioSciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools